Jabra Enhance Select 500 vs Otofonix Groove

The Jabra Enhance Select 500 is a premium behind-the-ear OTC hearing aid priced at $1,995 that earns an A grade with a SoundScore of 4.2/5 in our lab testing. This places it in the top 18% of the OTC hearing aid category, ranking #13 among 65 tested devices. In our testing, speech clarity in quiet environments stands out as a key strength, scoring 4.3/5—a strong result that measures 1.50 points above the category average. Feedback handling is excellent at 4.6/5, ensuring stable performance during everyday movements. Music streaming quality scores 2.9/5, which is 0.98 points above the category average but only mixed in absolute terms. The device shows some limitations worth noting. Speech understanding in noisy environments scores 1.8/5, which is above the category average by 0.31 points but low in absolute terms—a common challenge across OTC devices. Own-voice comfort scores 2.2/5, falling 0.31 points below the category average, which may be noticeable for users sensitive to how their own voice sounds. This two-time Expert's Choice Award winner (2023, 2024) offers rechargeable batteries and streaming compatibility with both iPhone and Android devices, including hands-free calling. Consumers seeking similar sound quality at a lower price point may want to compare the Jabra Enhance Select 300 or Lucid Engage. The Enhance Select 500 is best suited for those prioritizing strong speech clarity in quieter settings and reliable streaming performance within the premium OTC segment.

The Otofonix Groove is a behind-the-ear prescription hearing aid priced at $795, earning a C grade with a SoundScore of 2.7/5 in our lab testing. This rechargeable BTE ranks #38 of 39 devices in the prescription hearing aid category, placing it in the bottom 5% of its class. In our testing, the Groove demonstrated excellent feedback handling at 5.0/5, scoring 0.28 points above the category average. This represents a genuine strength, with the device maintaining stability during our standardized challenge motions. However, speech performance was significantly limited, with speech in quiet scoring 1.0/5 (2.40 points below the category average of 3.40) and speech in noise also at 1.0/5 (1.11 points below average). Music streaming was not functional in our tests, scoring 0.0/5 against a category average of 2.76. Own-voice comfort also fell well below typical prescription hearing aid performance at 0.4/5, which is 2.30 points below the category average. At this price point, several lower-cost alternatives delivered stronger overall performance in our testing. Consumers seeking value in the prescription category may want to explore other options, though those requiring robust feedback control in a rechargeable BTE format may find the Groove's stability noteworthy despite its other limitations.